Netherlands· NL-c1a213933b74
Atgam 50 mg/ml concentraat voor oplossing voor infusie
A antilymphocyte immunoglobulin (horse) product containing anti t-lymfocyt immunoglobuline, paard, registered in Netherlands by Pfizer B.V.. The same ATC class is registered in 9 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Antilymphocyte immunoglobulin (horse) is registered in 9 of 19 countries.
Countries holding a registration under ATC L04AA03 (antilymphocyte immunoglobulin (horse)), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 5 of them publish a price we can compare per daily dose
Antilymphocyte immunoglobulin (horse) · ATC L04AA03
9 / 19 countries
- Belgiumprice
- Canada
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ANTI T-LYMFOCYT IMMUNOGLOBULINE, PAARD
- Manufacturer
- Pfizer B.V.
- Country
- Netherlands (NL)
- ATC code
- L04AA03
- ATC class
- Antilymphocyte immunoglobulin (horse)
- Defined daily dose
- 1.05 g, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id126265
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L04AA03
Antilymphocyte immunoglobulin (horse), as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ab8f8571-a05e-45ee-8e47-23afdccbaca0 GET /v1/drugs/ab8f8571-a05e-45ee-8e47-23afdccbaca0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h126265_smpc.pdf",
"strength": null,
"atc_label": "Antilymphocyte Immunoglobulin (Horse)",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg126265",
"excipients": [
"GLYCINE (E 640)",
"NATRIUMHYDROXIDE (E 524)",
"WATER VOOR INJECTIE",
"ZOUTZUUR (E 507)"
],
"substances": [
"ANTI T-LYMFOCYT IMMUNOGLOBULINE, PAARD"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h126265.pdf",
"authorised_at": "2022/02/21",
"procedure_number": "DE/H/4910/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "126265",
"additional_monitoring": "Y"
}See everything about antilymphocyte immunoglobulin (horse).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.